GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ACADIA Pharmaceuticals ACAD · USD

Health Care · US listing · 🇺🇸 United States

Compare

17.11

-2.73%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

ACADIA Pharmaceuticals — daily ACAD Delayed
Market value
$2.84bn
Last close × shares
Volume
1.9m
Shares, 20 Nov 2026
Price to earnings
15.8

About ACADIA Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

ACADIA Pharmaceuticals is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACAD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.07bn and net income of $391.0m. At that date it held total assets of $1.56bn and shareholders' equity of $1.23bn. By business, NUPLAZID brought in 63.5% of revenue, followed by DAYBUE at 36.5%.

In its own words

We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.

We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Our rare disease franchise is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Net product sales from these two commercial products totaled $1,071.5 million for 2025, compared with $957.8 million for 2024.

In addition to these commercial products, we have a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in neurological and rare diseases. In order to achieve significant long-term growth, we plan to develop our current portfolio, expand our pipeline of early- and late-stage product candidates and expand into areas of rare disease that are adjacent to our existing franchises, including through strategic business development, and make use of our internal capabilities and knowledge.

Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗

More about ACADIA Pharmaceuticals →

Latest on ACADIA Pharmaceuticals

Our reporting

Next results

24 Feb 2027

Due on 24 Feb 2027. Analysts expect earnings of 0.28 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is ACADIA Pharmaceuticals's ticker?

ACADIA Pharmaceuticals trades as ACAD on its US listing, under ISIN US0042251084.

What was ACADIA Pharmaceuticals's last closing price?

17.11 on 20 Nov 2026. The figure is in USD and is never converted.

When does ACADIA Pharmaceuticals next report results?

Results are expected on 1 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.